Global Critical Care Therapeutics Market to Reach $7.4 Billion by 2030
The global market for Critical Care Therapeutics estimated at US$4.8 Billion in the year 2022, is projected to reach a revised size of US$7.4 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2022-2030. Albumin, one of the segments analyzed in the report, is projected to record 6.8% CAGR and reach US$3.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Prothrombin Complex Concentrates segment is readjusted to a revised 4.5% CAGR for the next 8-year period.The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 9% CAGR
The Critical Care Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.1% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.Select Competitors (Total 37 Featured) -
- Abeona Therapeutics Inc.
- ADMA Biologics, Inc.
- Albumedix Ltd.
- Asklepios Biopharmaceutical, Inc.
- Aspen Pharmacare Holdings Ltd.
- Baxter International Inc.
- Bayer Healthcare AG
- Bio Products Laboratory Ltd.
- BioDelivery Sciences International, Inc.
- Biogen, Inc.
- BioMarin Pharmaceutical Inc.
- Biotest Pharmaceuticals Corporation
- Bristol-Myers Squibb Company
- Catalyst Biosciences, Inc.
- China Biologic Products Holdings, Inc.
- Cosmo Pharmaceuticals NV
- CSL Behring
- Grifols International SA
- Kamada Ltd.
- Kedrion Biopharma, Inc.
- Medxbio Pte. Ltd.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novo Nordisk A/S
- Novozymes A/S
- Octapharma AG
- Portola Pharmaceuticals, Inc.
- ProMetic Life Sciences, Inc.
- rEVO Biologics, Inc.
- Rockwell Medical
- Sanquin
- Shanghai RAAS Blood Products Co., Ltd.
- Shire PLC
- Teva Pharmaceutical Industries Ltd.
- The Medicines Company
- Thermo Fisher Scientific, Inc.
- Ventria Bioscience
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abeona Therapeutics Inc.
- ADMA Biologics, Inc.
- Albumedix Ltd.
- Asklepios Biopharmaceutical, Inc.
- Aspen Pharmacare Holdings Ltd.
- Baxter International Inc.
- Bayer Healthcare AG
- Bio Products Laboratory Ltd.
- BioDelivery Sciences International, Inc.
- Biogen, Inc.
- BioMarin Pharmaceutical Inc.
- Biotest Pharmaceuticals Corporation
- Bristol-Myers Squibb Company
- Catalyst Biosciences, Inc.
- China Biologic Products Holdings, Inc.
- Cosmo Pharmaceuticals NV
- CSL Behring
- Grifols International SA
- Kamada Ltd.
- Kedrion Biopharma, Inc.
- Medxbio Pte. Ltd.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novo Nordisk A/S
- Novozymes A/S
- Octapharma AG
- Portola Pharmaceuticals, Inc.
- ProMetic Life Sciences, Inc.
- rEVO Biologics, Inc.
- Rockwell Medical
- Sanquin
- Shanghai RAAS Blood Products Co., Ltd.
- Shire PLC
- Teva Pharmaceutical Industries Ltd.
- The Medicines Company
- Thermo Fisher Scientific, Inc.
- Ventria Bioscience
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 242 |
Published | March 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 4.8 Billion |
Forecasted Market Value ( USD | $ 7.4 Billion |
Compound Annual Growth Rate | 5.6% |
Regions Covered | Global |